BCLI Brainstorm Cell Therapeutics Inc

USD 0.56 -0.04 -5.914695
Icon

Brainstorm Cell Therapeutics Inc (BCLI) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.5647

-0.04 (-5.91)%

USD 0.03B

0.65M

USD 0.00(+0.00%)

N/A

Icon

BCLI

Brainstorm Cell Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 0.56
0.00 0
Take a Tour
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.03B

N/A

USD 0.56

Brainstorm Cell Therapeutics Inc (BCLI) Stock Forecast

N/A
(+0.00%)

Based on the Brainstorm Cell Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Brainstorm Cell Therapeutics Inc is not available over the next 12 months. Brainstorm Cell Therapeutics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Brainstorm Cell Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Brainstorm Cell Therapeutics Inc’s stock price was USD 0.5647. Brainstorm Cell Therapeutics Inc’s stock price has changed by +17.65% over the past week, +54.04% over the past month and -69.31% over the last year.

No recent analyst target price found for Brainstorm Cell Therapeutics Inc
No recent average analyst rating found for Brainstorm Cell Therapeutics Inc

Company Overview Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture...Read More

1325 Avenue of Americas, New York, NY, United States, 10019

42

December

USD

USA

Adjusted Closing Price for Brainstorm Cell Therapeutics Inc (BCLI)

Loading...

Unadjusted Closing Price for Brainstorm Cell Therapeutics Inc (BCLI)

Loading...

Share Trading Volume for Brainstorm Cell Therapeutics Inc Shares

Loading...

Compare Performance of Brainstorm Cell Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BCLI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Brainstorm Cell Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing BCLI

Symbol Name BCLI's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Brainstorm Cell Therapeutics Inc (BCLI) Stock

Based on ratings from 0 analysts Brainstorm Cell Therapeutics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on BCLI's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BCLI's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BCLI's stock to indicate if its overvalued.

The last closing price of BCLI's stock was USD 0.56.

The most recent market capitalization for BCLI is USD 0.03B.

Unfortunately we do not have enough analyst data on BCLI's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Brainstorm Cell Therapeutics Inc's stock.

As per our most recent records Brainstorm Cell Therapeutics Inc has 42 Employees.

Brainstorm Cell Therapeutics Inc's registered address is 1325 Avenue of Americas, New York, NY, United States, 10019. You can get more information about it from Brainstorm Cell Therapeutics Inc's website at https://www.brainstorm-cell.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...